Pelthos Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pelthos Therapeutics Inc. (NYSE American: PTHS) on April 10, 2026. The filing reports significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer and the departure of the previous CFO.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and employment terms.
Material Changes
- Appointment of New CFO: John M. Gay was appointed Chief Financial Officer, Treasurer, and Secretary, effective April 10, 2026. He previously served as Senior Vice President, Finance & Accounting since July 2025.
- Departure of Former CFO: Francis Knuettel II was terminated from his position as Chief Financial Officer, effective April 10, 2026. His roles as Treasurer and Secretary were transitioned to Mr. Gay.
- Reason for Departure: The Board stated Mr. Knuettel's termination was not the result of any disagreement regarding the Company's operations, policies, or practices.
Compensation and Outlook
Employment Terms for John M. Gay:
- Base Salary: $425,000 annually.
- Annual Bonus: Target of 40% of base salary, contingent on meeting annual goals set by the Company and Board.
- Agreement Date: Effective April 10, 2026.
Separation of Francis Knuettel II: The Company expects to enter into a separation agreement pursuant to his existing employment agreement. Material terms of this separation will be disclosed in a future filing if required.
Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements related to product development, clinical trials, market opportunity, and financing. Actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the terms of the separation agreement for Francis Knuettel II in future filings.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed provisions on termination, equity, and benefits.
- Monitor upcoming financial reports (10-Q or 10-K) for the first financial data under the new CFO's tenure.
- Confirm the status of the Company's cash runway and financing needs, as this filing does not address liquidity.